Array BioPharma Reports Financial Results For The Third Quarter Of Fiscal 2017
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Array BioPharma (ARRY) PT Raised to $9 at Jefferies; Reiterates Buy
May 11, 2017 8:49 AM EDTJefferies raised its price target on Array BioPharma (NASDAQ: ARRY) to $9.00 (from $8.00) while maintaining a Buy rating. Lower 3Q reimbursement revenues of $26M from Novartis resulted in ~11% lower revenue of ~$33M (vs. ~$37M estimates).
For bini/enco in BRAFm CRC, assuming FDA... More
Array Biopharma (ARRY) Misses Q3 EPS by 4c
May 10, 2017 8:02 AM EDTArray Biopharma (NASDAQ: ARRY) reported Q3 EPS of ($0.21), $0.04 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $33.3 million versus the consensus estimate of $36.99 million.
For earnings history and earnings-related data on Array Biopharma (ARRY) click here.
... More